The structural profiles are close, with Jazz Pharmaceuticals carrying a narrow edge on valuation. Elanco Animal Health still has the edge on valuation, which keeps the comparison from looking entirely one-sided. The market setup is broadly comparable for both — no clear directional signal from price behavior. The market is not adding a decisive signal either way — the structural read carries the weight.
The comparison is based on similar long-term financial trajectories, not sector labels. Both peer scores are relative to the Russell 1000 universe, making them directly comparable.
The page question resolves through valuation, where Elanco Animal Health Incorporated holds the stronger read even though the broader score still favours Jazz Pharmaceuticals plc.
This comparison is anchored in long-term financial trajectory similarity within the selected peer universe.
This level of similarity signals a strong structural match, even though some dimensions still separate the two companies.
The clearest structural overlap shows up in investment intensity and margin consistency.
Scores reflect position relative to comparable companies with similar long-term financial trajectories.
The largest gaps do not all point in the same direction.
Left means cheaper relative valuation. Higher means stronger structure.
Jazz Pharmaceuticals plc occupies the cheaper side of the setup map, although Elanco Animal Health Incorporated still holds the stronger structural profile.
Valuation position uses Forward P/E and peer-relative PE percentile (idx_pct_pe) where available.
Where ELAN and JAZZ each sit in their own 5-year price and valuation history.
Describes historical entry positioning only. Descriptive — not investment advice.
The multiple-based pricing edge comes from a forward P/E that is 11.5 turns lower.
Elanco Animal Health Incorporated still shows lower market-fundamental divergence, which keeps the wider picture mixed rather than completely one-sided.
The lead is built on both valuation and growth — though valuation still provides a counterweight.
Break down the ELAN vs JAZZ comparison across all dimensions with the full interactive tool.
Explore how ELAN and JAZZ each compare against other companies in their peer groups.
Rule-based, descriptive analysis only. Derived from peer percentile dimensions. Not investment advice. Peer groups are determined algorithmically based on structural similarity — not by sector classification alone.
AssetNext scores reflect each company's structural position within its functional peer group — not a ranking against all stocks simultaneously. Peers are identified by similarity across eight financial dimensions, including revenue growth trajectory, margin structure, capital intensity, and earnings stability. A score of 75 means the company ranks in the top quartile within its own peer group, not the entire market.
Four dimension scores drive the overall peer score: Growth (revenue trajectory and expansion dynamics), Quality (margin structure and capital efficiency), Valuation (peer-relative pricing on standard multiples), and Stability (earnings consistency and financial predictability). Each dimension is scored 0–100 relative to the peer group, then combined into an overall peer score using equal weighting.
Because scores are peer-relative, the same company can have slightly different scores in different index universes. On comparison pages, both companies are shown within their shared peer universe wherever possible — so the scores are directly comparable. The peer basis is stated on each score card.
Scores are recalculated periodically as underlying financial data is updated. All analysis is descriptive and rule-based — AssetNext describes structural realities and never issues buy, sell or hold recommendations.